RecruitingNCT06490003
Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma
Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma by Biopsy Specimens.
Sponsor
City of Hope Medical Center
Enrollment
150 participants
Start Date
Jun 1, 2004
Study Type
OBSERVATIONAL
Conditions
Summary
Esophageal cancer remains a disease with a poor prognosis. Chemotherapy is an important part of its treatment, but there are cases in which chemotherapy is ineffective. The investigators aim to develop a model to predict the response to chemotherapy by DNA methylation of preoperative biopsy specimens to identify the chemotherapy ineffective group.
Eligibility
Min Age: 20 Years
Inclusion Criteria4
- Patients who had histologically confirmed esophageal squamous cell carcinoma.
- Patients who had undergone chemotherapy.
- Patients receiving initial chemotherapy
- Written informed consent following full study information is provided to the patient.
Exclusion Criteria3
- Patients for whom a preoperative biopsy sample cannot be obtained
- Patients who cannot assess at 2 months later after chemotherapy.
- Patients with multiple cancers.
Interventions
DRUGFluoro Uracil
Esophageal cancer chemotherapy（First line treatment)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06490003
Related Trials
Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC
NCT074031361 location
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632154 locations
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
NCT072171718 locations
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
NCT0678011141 locations
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
NCT0674758538 locations